Sulfation Pathways During Neurodevelopment

Taylor Clarke¹, Francesca E. Fernandez¹ and Paul A. Dawson²*

¹School of Behavioural and Health Sciences, Faculty of Health Sciences, Australian Catholic University, Banyo, QLD, Australia, ²Mater Research Institute, University of Queensland, Brisbane, QLD, Australia

Sulfate is an important nutrient that modulates a diverse range of molecular and cellular functions in mammalian physiology. Over the past 2 decades, animal studies have linked numerous sulfate maintenance genes with neurological phenotypes, including seizures, impaired neurodevelopment, and behavioral abnormalities. Despite sulfation pathways being highly conserved between humans and animals, less than one third of all known sulfate maintenance genes are clinically reportable. In this review, we curated the temporal and spatial expression of 91 sulfate maintenance genes in human fetal brain from 4 to 17 weeks post conception using the online Human Developmental Biology Resource Expression. In addition, we performed a systematic search of PubMed and Embase, identifying those sulfate maintenance genes linked to atypical neurological phenotypes in humans and animals. Those findings, together with a search of the Online Mendelian Inheritance in Man database, identified a total of 18 candidate neurological dysfunction genes that are not yet considered in clinical settings. Collectively, this article provides an overview of sulfate biology genes to inform future investigations of perturbed sulfate homeostasis associated with neurological conditions.

Keywords: sulfate, brain, embryological, fetal, gene expression, neurological dysfunction

INTRODUCTION

Sulfate is essential for healthy growth and development (Dawson, 2011). Supplied from the diet and catabolism of sulfur-containing amino acids, intracellular sulfate is transformed into 3′-phosphoadenosine 5′-phosphosulfate (PAPS) which is the universal sulfate donor for sulfate conjugation (sulfonation) to a wide range of endogenous and exogenous molecules via sulfotransferases (Mulder and Jakoby, 1990). Sulfonation biotransforms the physiological properties of molecules, including: (i) inactivation of steroids, thyroid hormone and neurotransmitters (Darras et al., 1999; Richard et al., 2001; Dawson, 2012); (ii) detoxification of xenobiotics and certain pharmaceutical drugs (McCarver and Hines, 2002); and (iii) maintenance of tissue structure and function via the sulfate content of glycosaminoglycans (Yamaguchi, 2001). Sulfatases remove sulfate from substrates to maintain the required balance of sulfonated to unconjugated substrates (Hanson et al., 2004). Disturbances in any of these sulfation pathways has the potential for adverse physiological consequences.

In recent years, interest in human sulfate biology has expanded following animal studies that show adverse phenotypes linked to sulfate biology genes (Langford et al., 2017). Neurological dysfunction is one of the most predominant phenotypes linked to disturbances of sulfate biology. This is not surprising when considering that sulfonation biotransforms numerous target molecules in the brain, including inactivation of thyroid hormone, metabolism of neurotransmitters (e.g., serotonin, noradrenaline and dopamine) and modulation of neurosteroid actions on GABAₐ, N-methyl-D-
aspartate (NMDA) glutaminergic and Ω-opioid receptors (Rivett et al., 1982; Kríz et al., 2008). Sulfonation of proteoglycans (e.g., heparan sulfate) and cerebroside sulfate also plays an important role in maintaining the structure and function of brain tissue (Schwartz and Domowicz, 2018). Animal studies have also shown that hyposulfataemia leads to reduced sulfonation capacity and abnormal behavioral phenotypes, including impaired memory, increased anxiety and seizures in mice (Dawson et al., 2003; Dawson et al., 2004; Dawson et al., 2005). More recent studies have shown that reduced transfer of sulfate across the blood-brain barrier of neonatal mice leads to: (i) decreased heparan sulfate levels in the subventricular zone (SVZ) and rostral migratory stream; (ii) impairment in perineuronal net formation (which contains sulfonated proteoglycans) in the hippocampus and somatosensory cortex; (iii) increased neural stem cell proliferation and decreased neuronal maturation in the SVZ; (iv) seizures; and (v) impaired behavioral phenotypes, including impaired long-term spatial memory and defects in social interaction and social memory (Zhang et al., 2020). Despite the diverse roles for sulfate during neurodevelopment, most human sulfate biology genes have not yet been considered in clinical genetics.

To date, 91 genes are known to contribute to maintaining sulfate homeostasis, including those encoding: sulfate transporters; PAPS synthetases and transporters; enzymes in the pathway of sulfate generation; cytosolic and membrane-bound sulfotransferases; and sulfatases (Langford et al., 2017). However, only 24 of these genes are currently considered in clinical genetics, with 16 of those genes linked to neurological dysfunction (Table 1). Animal studies have shown additional sulfate biology genes are linked to adverse neurological phenotypes (Langford et al., 2017), suggesting that the number of clinically reportable genes is currently underestimated. This warrants further investigation into the role of sulfate biology genes in human neurophysiology.

In this study, we curated the temporal and spatial mRNA expression patterns of all known sulfate biology genes in the developing human fetal brain between 4 and 17 weeks gestation, corresponding to a critical time for nervous system formation in utero. We show moderate to abundant mRNA expression levels

| TABLE 1 | Sulfate biology genes that are either clinically reportable or not yet captured in clinical genetics. |
|----------|---------------------------------------------------------------------------------------------------------------|
| Genes that have been investigated in research settings but are not yet captured in clinical resources |
| **Green** | **Amber** | **Red** |
| Sulfate transporters | | | |
| SLC4A1 | SLC26A1 | SLC13A1, SLC13A4, SLC26A6, SLC26A8, SLC26A9, SLC26A11 |
| SLC26A2 | | |
| SLC26A3 | | |
| SLC26A7 | | |
| SLC26A8 | | |
| PAPS synthetases | | |
| PAPSS2 | | |
| PAPS transporters | | |
| SLC35B2, SLC35B3 | | |
| Key enzymes in the pathways of sulfate generation | | |
| CBS | CTH | GTO1, SQOR, TST |
| CTH | | |
| SUOX | | |
| Cytosolic sulfotransferases | | |
| SULT1B1 | SULT1A1, SULT1A2, SULT1A3, SULT1A4, SULT1B1, SULT1C2, SULT1C3, SULT1C4, SULT1C5, SULT1C6, SULT2A1, SULT4A1, SULT6B1 |
| Membrane-bound sulfotransferases | | |
| CHST3 | CHST11 | CHST8 |
| CHST6 | HS2ST1 | HS2ST1 |
| CHST14 | HS6ST1 | | |
| NDST1 | | |
| Sulfatases and sulfatase modifying factors | | |
| ARSA | ARSB | ARSD, ARSF, ARSG, ARSH, ARSJ, ARSK, SULF1, SULF2 |
| ST3 | | SUMF2 |
| ST5 | | |
| ARSE | | |
| ARSI | | |
| GALNS | | |
| GNS | | |
| IDS | | |
| SGSH | | |

*Genes captured in clinical resources and coded green (high level of evidence), amber (medium level evidence, not yet used) and red (no strong evidence, do no use) by searching the online PanelAPP (https://panelapp.aghia.umccr.org/) consensus diagnostic gene panels (Martin et al., 2019) 18–19 January 2022. | | |
| Linked to adverse neurological phenotype. | | |
of 62 genes, suggesting a critical role of sulfate in early neurodevelopment. Additionally, we collated 18 sulfate biology genes implicated in atypical neurological function from the animal and human research literature which are currently not captured in clinical resources. Overall, these findings provide data for future investigations of sulfate biology genes associated with neurological dysfunction.

SULFATE BIOLOGY GENE EXPRESSION IN HUMAN FETAL BRAIN

We obtained data of gene expression in the human fetal brain from the online Human Developmental Biology Resource (HDBR) Expression (Lindsay et al., 2016) (https://www.hdbr.org/) from 6 November 2021 to 12 January 2022. The HDBR is one of the rare human fetal tissue databases providing gene expression under 8 weeks post-conception compared to other databases (Johnson et al., 2009; Sunkin et al., 2013), which is essential for getting a better understanding of brain development since neurulation starts after 3 weeks post-conception (O’Rahilly and Müller, 1994). Taking in account that brain development is dynamic, HDBR reports anatomical regionalisation gene expression results, which is also essential for mapping the differential pattern of gene expression related to selected brain regions compared to using full brain tissues (Ono et al., 2017). Data were available for four brain regions (cerebrum, brainstem, diencephalon and cerebellum) from 4 to 17 weeks post-conception. The gene expression levels for each tissue sample were averaged for each set of technical replicates, and then quantile normalized within each set of biological replicates using limma. Finally, they are averaged for all biological replicates. Specifically, we used transcripts per million (TPM) mapped reads-normalized RNA-Seq data to plot results for each gene. Of the 91 sulfate biology genes, 16 were abundantly expressed (>100 TPM) in at least one brain region at one gestational time point, 46 genes had moderate (>10 to 100 TPM) mRNA expression, and 15 genes had lower (≥0.1 to 10 TPM) mRNA expression levels (Figures 1–4). Fourteen genes (SLC13A1, SLC26A3, SLC26A9, SULT1A4, SULT1C3, SULT2A1, SULT2B1, SULT6B1, CHST4, CHST13, GAL3ST2, HS3ST6, ARSH and ARS5) had undetectable or negligible (<0.1 TPM) mRNA expression levels (data not shown). The limitations of these data are that mRNA levels may: (i) not be representative of encoded protein level; (ii) be predictive of functional impact when abnormal, for example altered expression of highly-expressed genes does not necessarily result in a more severe neurodevelopmental phenotype than altered expression of lowly-expressed genes; (iii) be redundant as other family member genes may compensate for altered expression level of a particular gene; (iv) not identify any sex-specific effects as the data are derived from pooled samples, which warrants future investigations to compare sulfate biology gene expression between male and female samples. Furthermore, our focus on genes expressed in the brain doesn’t take into account any of the sulfate biology genes expressed in other tissues that may influence neurodevelopment, such as the thyroid or adrenal gland or testis that could theoretically influence neurodevelopment through endocrine effects. Nonetheless, the temporal and spatial mRNA expression profiles of sulfate biology genes reported in the present study provide information for the next phase of research into understanding the regulation of sulfate homeostasis in the developing brain.

Genes Involved in Sulfate and PAPS Supply

Amongst the most abundantly expressed sulfate biology genes at all gestational time points are those involved in: (i) transporting sulfate from circulation to brain across the blood brain barrier (SLC13A4) (Zhang et al., 2020); (ii) the major (CDO1) and minor (CTH) biochemical pathways of sulfate generation (Dawson et al., 2020); and (iii) synthesis (PAPSS1) and transportation (SLC35B2 and SLC35B3) of PAPS (Langford et al., 2017) (Figure 1). SLC13A4 mRNA expression was specifically expressed in the cerebrum, indicating that sulfate transport from circulation likely contributes an important role in sulfate supply in early neurodevelopment. Of great interest are the data showing abundant mRNA expression of those genes involved in pathways of sulfate generation from the sulfur-containing amino acid cysteine. Previous studies suggested that the developing fetus has negligent capacity to generate sulfate, based on low CDO1 and CTH mRNA expression levels in the liver (Gaul et al., 1972; Loriette and Chatagner, 1978). However, a more recent animal study showed the expression of Cdo1 mRNA in the developing mouse fetus from mid-gestation (Rakoczky et al., 2015). The present study shows abundant expression of CDO1, suggesting that the fetal brain most likely generates sulfate, in addition to obtaining sulfate from circulation via SLC13A4. The present study also shows that PAPSS1 is the most abundantly expressed sulfate biology gene in all four selected regions of the fetal brain, suggesting that this gene encodes for the predominant PAPS synthetase in fetal brain tissue, rather than PAPSS2 which is expressed in cartilage and linked to developmental dwarfism disorders (Bownass et al., 2019). In addition, the findings of abundant SLC35B2 and SLC35B3 mRNA expression suggest that PAPS is actively transported in the golgi of fetal brain cells for sulfonation reactions via membrane-bound sulfotransferases. Collectively, these findings of abundant mRNA expression of genes involved in sulfate supply and generation, as well as generation and transport of PAPS, suggest that sulfate has an important physiological role in early fetal neurodevelopment.

Sulfotransferase Genes

There are two classes of sulfotransferases based on their protein sub-cellular localization: (i) cytosolic sulfotransferases which sulfonate neurotransmitters, bile acids, xenobiotics and steroids; and (ii) membrane-bound sulfotransferases that sulfonate proteoglycan and lipid molecules (Gamage et al., 2006). The present study shows abundant mRNA levels of four cytosolic (Figure 2) and 22 membrane-bound (Figure 3) sulfotransferases. SULT4A1 is the most abundantly expressed cytosolic sulfotransferase mRNA in all four fetal brain regions. Whilst the substrate of SULT4A1-mediated sulfonation has not yet been identified, a recent study suggests it plays a role in the regulation of neuronal morphology and synaptic activity.
et al., 2020). Abundant mRNA levels of SULT1E1 and SULT1C4, suggest that these two sulfotransferases, that sulfonate estrogenic compounds (Dawson, 2012), may regulate hormonal signalling pathways during fetal neurodevelopment. Interestingly, SULT1E1 mRNA is mainly expressed in cerebrum, which is a critical region in hormonal regulation due to its development into the thalamic and hypothalamic structures modulating endocrine body system. SULT1A1 mRNA expression was abundant in the cerebrum, with lower levels detected in the other three brain regions. SULT1A1 sulfonates phenolic compounds, and while it has a major role of Phase II metabolism in the liver (Paci fi ci, 2005), it is also proposed to contribute to the detoxification and clearance of drugs and toxins in the brain (Salman et al., 2009). It is intriguing to see a single burst of abundant SULT1B1, iodothyronine sulfotransferase (Stanley et al., 2005), mRNA expression at 10 weeks post-conception. This time point coincides with the early stage of neuronal migration, a neurodevelopmental process that relies on the action of thyroid hormone which is regulated by SULT1B1-mediated sulfonation (Wang et al., 1998; Morreale de Escobar et al., 2004). In addition to the cytosolic sulfotransferases, the majority of all known membrane-bound sulfotransferases were abundantly expressed (Figure 3), including: carbohydrate sulfotransferases CHST1, CHST2, CHST3, CHST8, CHST10, CHST11, CHST14, and CHST15; galactose 3-O-sulfotransferases GAL3ST3 and GAL3ST4; heparan sulfate 2-O-sulfotransferase HS2ST1; heparan sulfate 3-O-sulfotransferases HS3ST2, HS3ST4, and HS3ST5; heparan sulfate 6-O-sulfotransferases HS6ST1, HS6ST2 and HS6ST3; FIGURE 1 | Spatial and temporal mRNA expression of sulfate transporters, PAPS synthetases and transporters, and enzymes in the pathways of sulfate generation in fetal brain regions (A) cerebrum, (B) brainstem, (C) diencephalon, and (D) cerebellum. dpc, days post-conception. TPM, transcripts per million.
heparan N-deacetylase/N-sulfotransferases NDST1 and NDST; tyrosylprotein sulfotransferase TPST1; and uronyl 2-sulfotransferase UST. Overall, these findings suggest the sulfonation of numerous substrates in the developing fetal brain.

**Sulfatase Genes**

The removal of sulfate from lipids, glycosaminoglycans and steroids is mediated by sulfatases (Hanson et al., 2004), of which nine are abundantly expressed in the fetal brain (Figure 4). This is relevant to sulfatases that target a range of substrates in the central nervous system, including sulfoglycolipids (ARSA), proteoglycans (ARSB, ARSK, GNS, IDS, SULF1 and SULF2) and steroids (STS). With the exception of STS, all of these sulfatase genes were expressed in all four brain regions over the 4–17 weeks gestational period. STS mRNA level is low in cerebrum when compared to brainstem, diencephalon and cerebellum, suggesting that steroid activity is spatially confined to the latter three brain regions during early neurodevelopment. **SULF1** and **SULF2** mRNA, highly expressed in developing fetal brain, lead to the formation of enzyme removing 6-O-sulfate groups of proteoglycans and modulating morphogen Shh gradient during embryonic development. By modifying the Shh gradient in the embryo, the regulation of motorneuron to oligodendrocyte precursor cell fate change is significantly affected in the developing ventral spinal cord (Jiang et al., 2017). The present study also shows abundant sulfatase modifying factor 2 (SUMF2) mRNA levels in comparison to low SUMF1 mRNA levels, indicating that SUMF2 is the major sulfatase regulating factor in early fetal brain tissue. There were short bursts of increased ARSI, GALNS and SGSH mRNA expression that were spatially enriched, suggesting a localized and temporary requirement for these glycosaminoglycans metabolizing sulfatases. Taken together, the abundant mRNA expression of numerous sulfatases indicates an active process of regulating sulfate content in the developing fetal brain.

**CANDIDATE NEUROLOGICAL DYSFUNCTION SULFATE BIOLOGY GENES**

Despite the mRNA expression of 62 sulfate biology genes in the fetal brain (Figures 1–4), only 12 of these genes are considered for neurological dysfunction in routine clinical genetics (Table 1). As an approach to inform clinical geneticists and potentially expand the list of clinically reportable genes, we undertook a systematic online search (10–23 September 2021). We used PubMed and Medline to identify sulfate biology genes reported to be associated with atypical neurological phenotypes in humans using the search...
FIGURE 3 | Spatial and temporal mRNA expression of membrane-bound sulfotransferases in fetal brain regions (A) cerebrum, (B) brainstem, (C) diencephalon, and (D) cerebellum. dpc, days post-conception. TPM, transcripts per million.
terms: (“brain” or “cerebellum” or “cerebral” or “neurodevelop”) and (“gene” or “dna” or “gene expression regulation” or “gene expression” or “gene genetic regulation”) and (“sulphate” or “sulfate” or “SO4”). We included articles that associated any of the sulfate biology genes with neurological conditions. All references used in this study were peer-reviewed research articles published in English between January 2001 and September 2021. In addition, we used OMIM (https://www.ncbi.nlm.nih.gov/omim/?term=) to expand our search prior to 2001 and to include any research articles not captured in our literature search. Overall, our research literature and OMIM searches identified 42 research articles that report the involvement of sulfate biology genes in neurological dysfunction.

From the curated list of research articles, we identified 18 candidate neurological dysfunction genes that are not yet clinically reportable (Table 2). Ten of these genes were reported from animal studies (SLC13A1, SLC13A4, SLC35B2, CDO1, CHST12, CHST15, NDST2, NDST3, SULF2 and UST), 2 from human and animal studies (ARSG and SULF1) and 6 from human research studies (SQOR, TST, SULT4A1, CHST10, HS6ST2 and ARSK). Thirteen of these genes are abundantly expressed in the human brain between 4 and 17 weeks gestation, whereas SQOR, CHST12, NDST2 and ARSG are expressed at low level (Figures 1–4) and SLC13A1 mRNA level is negligible (data not shown). The SLC13A1 gene is primarily expressed in the proximal tubule of the kidney where it mediates sulfate reabsorption (Ullrich and Murer, 1982; Lee et al., 2005). Disruption of human SLC13A1 and mouse Slc13a1 causes renal sulfate wasting and hyposulfataemia, which is proposed to reduce sulfate supply to the brain (Dawson et al., 2003; Bowling et al., 2012). Sulfide: quinone oxidoreductase (SQOR) is an enzyme in the minor

---

**Figure 4** | Spatial and temporal mRNA expression of sulfatases and sulfatase modifying factors in fetal brain regions (A) cerebrum, (B) brainstem, (C) diencephalon, and (D) cerebellum. dpc, days post-conception. TPM, transcripts per million.
pathway of sulfate generation (Dawson, 2013) and its loss leads to excess hydrogen sulfide levels that cause encephalopathy and Leigh disease (Friederich et al., 2020). Individuals with SQOR mutations first present with coma in early childhood (Friederich et al., 2020), suggesting a physiological role for SQOR in the brain beyond the 17-week gestational end point used to assess gene expression in the present study. Increasing CHST12, NDST2, and ARSG mRNA levels in brain at developmental ages beyond 17 weeks gestation (Humphries et al., 1998; Hiraoka et al., 2000; Khateb et al., 2018), also explains their low mRNA levels presented in this study. Nonetheless, the 18 genes listed in Table 2, warrant further research to determine whether these candidate neurological dysfunction genes are to be considered in clinical genetics.

**SUMMARY**

In this study, we show the moderate to abundant mRNA expression of 62 sulfate biology genes in the human fetal brain between 4 and 17 weeks post-conception, a critical period in nervous system formation. This relatively large number of genes highlights the physiological relevance of sulfate in neurodevelopment and is a testament to the genetic complexity of maintaining sulfate homeostasis. However, sulfate biology is underappreciated in clinical settings, with only 12 genes routinely considered for certain neurological conditions. Our finding of an additional 18 genes reported in the research literature with neurological dysfunction, warrants future studies to validate the pathogenetics of these genes in human brain. Expanding the list of clinically reportable sulfate biology genes has the potential for improved genetic counselling, and potentially for developing therapeutic approaches towards clinical treatments. Overall, this study curated a list of sulfate biology genes involved in early brain development that provide information for future research of the physiological roles and regulation of sulfate homeostasis in human brain.

**AUTHOR CONTRIBUTIONS**

This study was designed by TC, FEF and PAD. Online searches were conducted by TC and PAD and all authors contributed to the preparation of the manuscript and approved the final version.

**FUNDING**

This study was funded by the Mater Foundation. PAD is supported by a Mater Foundation Principal Research Fellowship.

**ACKNOWLEDGMENTS**

We acknowledge the administrative and IT support of Mater Research Ltd. for this research that was carried out in part at the Translational Research Institute (TRI), which is supported by a grant from the Australian Government.

**TABLE 2** | Neurological phenotypes reported for sulfate biology genes that are not yet captured in clinical genetics.

| Gene | Phenotypes (References) |
|------|-------------------------|
| **Sulfate transporters** | |
| SLC13A1 | Mice: seizures, behavioural abnormalities (Dawson et al., 2003; Dawson et al., 2004; Dawson et al., 2005) |
| SLC13A4 | Mice: impaired social behavior and neurogenesis (Zhang et al., 2019; Zhang et al., 2020) |
| **PAPS transporters** | |
| SLC35B2 | Drosophila: pupal lethality (Kamiyama et al., 2003) |
| **Key enzymes in the pathways of sulfate generation** | |
| CDO1 | Mice: fetal death and irregular shaped cranium (Ueki et al., 2011) |
| SQOR | Human: encephalopathy, seizures, coma, Leigh syndrome-like brain lesions (Friederich et al., 2020) |
| TST | Human: Leber optic atrophy (Cagianut et al., 1981) |
| **Cytosolic sulfotransferases** | |
| SULT4A1 | Human: perturbed dendritic morphology and synaptic activity (Cuótta et al., 2020) |
| **Membrane-bound sulfotransferases** | |
| CHST10 | Human: T cell invasion and nerve damage during inflammation (Dasgupta et al., 2009) |
| CHST12 | Mice: adverse cerebellar development (Hshi and Maeda, 2008) |
| CHST15 | Mice: adverse cerebellar development (Hshi and Maeda, 2008) |
| HS6ST2 | Human: Global developmental delay, intellectual disability, enlarged lateral ventricles (Paganini et al., 2019) |
| NDST2 | Mice: Induction of neural cells (Forsberg et al., 2012) |
| NDST3 | Mice: subtle behavioral abnormalities (Palmerla et al., 2008) |
| UST | Mice: adverse cerebellar development (Hshi and Maeda, 2008) |
| **Sulfatases and sulfatase modifying factors** | |
| ARSG | Human: Usher syndrome, Type IV (Abad-Morales et al., 2020; Fowler et al., 2021; Peter et al., 2021). Dog: cerebellar ataxia, neuronal ceroid lipofuscinosis (Adtiobol et al., 2010) |
| ARSK | Human: Mucopolysaccharidosis type X (Verheyen et al., 2021) |
| SULF1 | Human: microcephaly, diffuse or multifocal cerebral dysfunction (Day-Salvatore and McLean, 1998). Mice: Reduced hippocampal spine density and impaired long-term potentiation in CA1 (Kalus et al., 2005) |
| SULF2 | Mice: Impaired generation of Olig2-expressing pMN-derived cell subtype (Chayon et al., 2019). Mice: Congenital hydrocephalus and impaired spatial learning (Kalus et al., 2009) |
| SULF1/2 | Mice: Corticospinal tract defects (Okada et al., 2017) |
Morreale de Escobar, G., Obregon, M., and Escobar del Rey, F. (2004). Role of Thyroid Hormone during Early Brain Development. *Eur. J. Endocrinol.* 151 (Suppl. 3), U25–U37. doi:10.1530/eje.0.151u025

Mulder, G. J., and Jakoby, W. B. (1990). “Sulfation,” in *Conjugation Reactions in Drug Metabolism: An Integrated Approach: Substrates, Co-substrates, Enzymes and Their Interactions in Vivo and in Vitro*. Editor G. J. Mulder (London: Taylor & Francis), 107–161.

O’Rahilly, R., and Müller, F. (1994). Neurulation in the normal Human Embryo. *Ciba Found. Symp.* 181, 70–89. ; discussion 82-79. doi:10.1002/cf.1816236261

Ohayon, D., Escalas, N., Cocheid, P., Glise, B., Danesin, C., and Soula, C. (2019). Sulfatase 2 Promotes Generation of a Spinal Cord Astrocyte Subtype that Stands Out through the Expression of Olig2. *Glia* 67 (8), 1478–1495. doi:10.1002/glia.23621

Okada, T., Keino-Masu, K., Nagamine, S., Kametani, F., Ohno, H., Okubo, K., and Bono, H. (2017). Knockout of the Murine Cysteine Dioxygenase Gene Results in Severe Impairment in Ability to Synthesize Taurine and an Increased Catabolism of Cysteine to Hydrogen Sulfide. *Am. J. Physiology-Endocrinology Metabol. 301* (4), E668–E684. doi:10.1152/ajpendo.00351.2011

Ulrich, K. J., and Murer, H. (1982). Sulphate and Phosphate Transport in the Renal Proximal Tubule. *Phil. Trans. R. Soc. B* 299, 549–558. doi:10.1098/rstb.1982.0151

Verheyen, S., Blatterer, J., Speicher, M. R., Bhavani, G. S., Goos, G.-J., Ilse, M.-B., et al. (2021). Novel Subtype of Mucopolysaccharidosis Caused by Arylsulfatase K (ARSK) Deficiency. *J. Med. Genet.*, 16, jmedgenet-2021. doi:10.1136/jmedgenet-2021-108061

Wang, J., Falany, J. L., and Falany, C. N. (1998). Expression and Characterization of a Novel Thyroid Hormone-Sulfating Form of Cytosolic Sulfotransferase from Human Liver. *Mol. Pharmacol.* 53 (2), 274–282. doi:10.1124/mol.53.2.274

Yamaguchi, Y. (2001). Heparan Sulfate Proteoglycans in the Nervous System: Their Diverse Roles in Neurogenesis, Axon Guidance, and Synaptogenesis. *Semin. Cell Developmental Biol.* 12 (2), 99–106. doi:10.1006/scdb.2000.0238

Zhang, Z., Dawson, P. A., Piper, M., and Simmons, D. G. (2019). Postnatal N-Acetylcysteine Administration Rescues Impaired Social Behaviors and Neurogenesis in Slc13a4 Haploinsufficient Mice. *ElifeMedicine* 43, 435–446. doi:10.1124/ebio.2019.03.081

Zhang, Z., Ihveri, D., Sharmin, S., Harvey, T. J., Dawson, P. A., Piper, M., et al. (2020). Cell-extrinsic Requirement for Sulfate in Regulating Hippocampal Neurogenesis. *Bioll Open* 9 (7). doi:10.1242/bio.053132

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Clarke, Fernandez and Dawson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.